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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S167Methods: This cross-sectional study includes members of the Fra-
mingham Foot Study. A validated exam of the foot was used to assess
the presence of hallux valgus, hallux rigidus, and plantar fasciitis. To
determine foot type, center of pressure excursion index (CPEI)
measurements were recorded using the TekScan Matscan (1.4 sensors/
cm2) system. CPEI is a dynamic measure of foot type that uses the
concavity of the center of pressure curve in the metatarsal head region,
normalized to foot width during the stance phase of gait. In a prior
study by Hillstrom et al., utilizing the emed-x plantar pressure system
(4 sensors/cm2), CPEI thresholds discriminated planus, rectus (normal
arch), and cavus (high arch) feet. Due to the differences in system
resolution, a scaling equation was developed in order to determine the
equivalent CPEI threshold on a TekScan Matscan system that differen-
tiated planus from non-planus (rectus and cavus) feet. This threshold
was deﬁned as a CPEI19.4% on a TekScan Matscan system. Crude and
adjusted logistic regression models, using generalized estimating
equations (GEE) to account for the correlation between left and right
feet, were used to calculate odds ratios for the relation between foot
type and the prevalence of hallux rigidus, hallux valgus, and plantar
fasciitis. Adjusted models included age, sex and body mass index (BMI).
Results: This study included 2,994 participants (5,778 feet) with an age
range of 36-98 years and 55% women. The results are shown in Table 1.
Approximately 74% of the study population (mean age¼65.59.9 years)
was classiﬁed as having pes planus in at least one foot. Those with ﬂat
feet were at an increased odds for hallux valgus (OR 1.6, 95% CI 1.4, 1.8)
and hallux rigidus (OR 1.6, 95% CI 1.1, 2.3). These results remained
signiﬁcant when adjusted for age, gender, and BMI.
Conclusions: Those with planus foot type had a higher odds of hallux
valgus and hallux rigidus, but not plantar fasciitis. The high prevalence
rate of pes planus in the Framingham cohort may be because the
average participant is 66 years old and arch height has been shown to
decrease with age. Further, CPEI recordings may be more sensitive to
less severe cases of pes planus, contributing to this high prevalence rate.
Hallux valgus and hallux rigidus was more prevalent in pes planus
versus non-planus feet. This is important because foot structure and
function are potentially modiﬁable factors for these pathologies that
have implications for prevention and treatment.Results from GEE logistic regression models assessing the odds of
foot pathology.
Hallux Valgus Hallux Rigidus Plantar Fasciitis
Prevalence (%) 49.6 5.9 6.6
Foot Type n (%) n (%) n (%)
Planus (CPEI19.4%) 29.1 3.6 3.2
Non-Planus (CPEI>19.4%) 20.5 2.3 3.4
Bivariate Model
(N¼5,781)
OR (95%CI) OR (95%CI) OR (95% CI)
Foot Type
Planus (CPEI19.4%) 1.6 (1.4-1.8) 1.6 (1.1-2.3) 0.97 (0.70-1.3)
Non-Planus
(CPEI>19.4%)
Ref Ref Ref
Hallux Valgus Hallux Rigidus Plantar Fasciitis
Multivariate
Model (N¼5,781)*
OR (95%CI) OR (95%CI) OR (95%CI)
Foot Type
Planus (CPEI19.4%) 1.2 (1.1-1.4) 1.5 (1.1-1.9) 0.89 (0.67-1.2)
Non-Planus (CPEI>19.4%) Ref Ref Ref
* Adjusted for age, gender, & BMI317
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Purpose: Opioids provide one treatment option for severe non-cancer
pain. In osteoarthritis the beneﬁts associated with the use of opioids arepresumably limited by frequent side effects, leading patients to with-
draw, switch/rotate to another opioid. The aim of this study was to
compare the risk of patients rotating opioid therapy from either
controlled-release (CR) morphine or CR oxycodone in opioid-naïve
patients with non-malignant pain.
Methods: By individual-level linkage of the Danish nationwide
administrative registries between 2005-2007, adult patients who were
prescribed either CR morphine or CR oxycodone, who had not previ-
ously been prescribed opioids (at least six months prior to “baseline”
deﬁned as the ﬁrst prescription of CR morphine or CR oxycodone), were
followed up for as long as 3 years (maximally until December 31, 2007).
Patients with a cancer diagnosis were excluded from the study and
subsequent analyses. Adjusted for age, sex, comorbidity, calendar year,
concomitant pharmacotherapy, income and social status, Hazard Ratios
(HR) for the association between opioid treatment (CR-oxycodone vs.
CR-morphine) and withdrawal from opioid therapy were analyzed by
Cox proportional-hazard models. The main outcome measure was the
number of patients switching from one type of opioid to another;
secondary outcome was the number of patients who were able to
withdraw from opioid therapy (i.e., no further need for opioid
analgesics).
Results: Of the 101,635 patients assessed for inclusion, 75,587 (74%)
had been prescribed opioids 6 months prior to enrolment and 4,818
(5%) had a cancer diagnosis. In total, 21,230 patients were enrolled,
16,553 (78%) were prescribed CR-oxycodone and 4,677 (22%) CR-
morphine. Of these, 5,750 (35%) CR-oxycodone patients and 2,166
(46%) CR-morphine patients switched to another opioid. After adjust-
ment, CR-oxycodone was associated with a statistically signiﬁcant
reduced risk for rotation (switch) to another opioid compared to CR
morphine; HR ¼ 0.82 (95%CI: 0.78-0.87; P<0.001). Among patients
still on therapy at time of censoring (possible drug addiction devel-
opment), 4.5% (112) were still using CR-morphine and 2.1% (231) were
using CR-oxycodone.
Conclusion: This study demonstrates a signiﬁcantly greater risk (18%)
for opioid rotation using CR-morphine compared with CR-oxycodone in
patients suffering from non-malignant pain.318
SIMULATION MODELING WITH SYSTEM DYNAMICS (SD) TO PLAN
OSTEOARTHRITIS CARE DELIVERY IN ALBERTA
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Purpose: Currently, there are no reliable and validated tools that health
service decision-makers can use to inform system level policy decisions.
To address this need, we worked with health administrators, clinicians
and researchers to create and validate a decision-support tool that
service planners can use to achieve a sustainable, integrated care
system for hip and knee osteoarthritis (OA).
Methods: The tool is based on a system dynamics (SD) model of patient
ﬂow across the continuum of care, including self-directed, primary,
rheumatologic and orthopaedic specialist, acute, and surgical follow-up
care. The model was developed in four phases: phase 1 focused on
demand and ﬂow rates, phase 2 on resource use and costs, phase 3 on
geographical stratiﬁcation, and phase 4 on adding feedback loops. We
populated the model with data from several sources, including Alberta
Health & Wellness (e.g. physician claims, inpatient, and ambulatory
data), Statistics Canada (e.g. the Survey of Living with Chronic Diseases
in Canada and population projections), and the Alberta Bone and Joint
Health Institute (clinical/surgical data). Using established principles of
SD modeling and an iterative, integrated knowledge translation process
involving multiple workshops with front-line clinical staff and admin-
istrators, we deﬁned the problem, determined the care process,
modeled the system as a series of stock and ﬂows, tested, validated and
calibrated the model.
Results:We have developed the full SD model, for two key applications.
First, it can help identify ﬂow, resource use and cost variations in
current practice, which may beneﬁt from further exploration. For
example, variations in practice patterns, particularly surgery rates and
resource use, were observed among the health zones reﬂecting regional
